Modalis Therapeutics Corporation
Research Modalis Therapeutics Corporation (4883.T) on Bullrun: market cap JPY 3.03B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4883.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 3.03B
- Financial periodFY2025
- RevenueJPY 0
- Net income-JPY 2.15B
- Free cash flow-JPY 2.12B
Valuation Snapshot
latest market cap is JPY 3.03B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 0 | -JPY 2.15B | -JPY 2.12B | n/a | -27.86 | JPY 2.81B | n/a | JPY 2.79B |
| FY2024 | JPY 0 | -JPY 1.32B | -JPY 1.43B | n/a | -28.57 | JPY 3.58B | JPY 0 | JPY 3.55B |
| FY2023 | JPY 0 | -JPY 2.39B | -JPY 2.29B | n/a | -77.24 | JPY 1.88B | JPY 412.50M | JPY 1.38B |
| FY2022 | JPY 40.50M | -JPY 2.70B | -JPY 2.09B | n/a | -92.85 | JPY 2.93B | JPY 0 | JPY 2.94B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 3.03B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Modalis Therapeutics Corporation's market cap?
Modalis Therapeutics Corporation's market capitalization is JPY 3.03B.
What does Modalis Therapeutics Corporation do?
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.